Market Closed -
Australian S.E.
11:40:06 08/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.06
AUD
|
-1.64%
|
|
-10.45%
|
-15.49%
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
74.36
|
58.24
|
35.18
|
185.9
|
56.99
|
12.57
|
Enterprise Value (EV)
1 |
65.03
|
59.26
|
33.08
|
159.5
|
43.14
|
9.558
|
P/E ratio
|
-3.51
x
|
-5.16
x
|
-82.5
x
|
-18.2
x
|
-3.04
x
|
-0.83
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
81.1
x
|
15.5
x
|
4.22
x
|
33.1
x
|
10.5
x
|
2.09
x
|
EV / Revenue
|
70.9
x
|
15.8
x
|
3.97
x
|
28.4
x
|
7.95
x
|
1.59
x
|
EV / EBITDA
|
-6.83
x
|
-5
x
|
-4.2
x
|
-11
x
|
-4.53
x
|
-0.91
x
|
EV / FCF
|
22.7
x
|
-12.7
x
|
-3.12
x
|
-32.2
x
|
-4.23
x
|
-1.37
x
|
FCF Yield
|
4.4%
|
-7.86%
|
-32.1%
|
-3.11%
|
-23.6%
|
-73.2%
|
Price to Book
|
7.33
x
|
-579
x
|
2.73
x
|
4.56
x
|
2.36
x
|
1.38
x
|
Nbr of stocks (in thousands)
|
1,21,901
|
1,22,601
|
2,13,201
|
2,88,222
|
2,92,238
|
2,92,238
|
Reference price
2 |
0.6100
|
0.4750
|
0.1650
|
0.6450
|
0.1950
|
0.0430
|
Announcement Date
|
30/08/18
|
29/08/19
|
31/08/20
|
26/08/21
|
25/08/22
|
31/08/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.9165
|
3.751
|
8.332
|
5.608
|
5.429
|
6.01
|
EBITDA
1 |
-9.525
|
-11.85
|
-7.868
|
-14.54
|
-9.518
|
-10.49
|
EBIT
1 |
-9.584
|
-11.91
|
-8.034
|
-14.59
|
-9.779
|
-10.64
|
Operating Margin
|
-1,045.69%
|
-317.63%
|
-96.42%
|
-260.22%
|
-180.14%
|
-177.12%
|
Earnings before Tax (EBT)
1 |
-18.32
|
-12.57
|
-0.9996
|
-9.347
|
-18.67
|
-15.06
|
Net income
1 |
-18.28
|
-11.22
|
-0.2721
|
-9.347
|
-18.67
|
-15.06
|
Net margin
|
-1,994.85%
|
-299.22%
|
-3.27%
|
-166.66%
|
-343.86%
|
-250.52%
|
EPS
2 |
-0.1739
|
-0.0920
|
-0.002000
|
-0.0354
|
-0.0641
|
-0.0515
|
Free Cash Flow
1 |
2.864
|
-4.658
|
-10.61
|
-4.956
|
-10.19
|
-6.998
|
FCF margin
|
312.52%
|
-124.18%
|
-127.35%
|
-88.37%
|
-187.8%
|
-116.44%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/08/18
|
29/08/19
|
31/08/20
|
26/08/21
|
25/08/22
|
31/08/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
1.02
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
9.33
|
-
|
2.1
|
26.4
|
13.9
|
3.01
|
Leverage (Debt/EBITDA)
|
-
|
-0.0861
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2.86
|
-4.66
|
-10.6
|
-4.96
|
-10.2
|
-7
|
ROE (net income / shareholders' equity)
|
-290%
|
-289%
|
-17.5%
|
-34.8%
|
-57.5%
|
-90.7%
|
ROA (Net income/ Total Assets)
|
-68.9%
|
-79%
|
-41.2%
|
-26.9%
|
-16.4%
|
-36.2%
|
Assets
1 |
26.52
|
14.21
|
0.6602
|
34.8
|
113.7
|
41.55
|
Book Value Per Share
2 |
0.0800
|
-0
|
0.0600
|
0.1400
|
0.0800
|
0.0300
|
Cash Flow per Share
2 |
0.1000
|
0.0200
|
0.0300
|
0.0900
|
0.0500
|
0.0100
|
Capex
1 |
0.31
|
0.01
|
0
|
-
|
-
|
-
|
Capex / Sales
|
34.08%
|
0.17%
|
0.04%
|
-
|
-
|
-
|
Announcement Date
|
30/08/18
|
29/08/19
|
31/08/20
|
26/08/21
|
25/08/22
|
31/08/23
|
|
1st Jan change
|
Capi.
|
---|
| -15.49% | 11.79M | | -2.35% | 89.33B | | +4.08% | 41.19B | | -15.09% | 31.87B | | +53.68% | 24.52B | | -15.13% | 15.68B | | -8.63% | 12.34B | | -40.39% | 12.23B | | +6.22% | 8.83B | | -6.43% | 8.28B |
Biopharmaceuticals
|